Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Divests German BioReliance Manufacturing Unit to Investor Group; Business Not Aligned With Invitrogen s Goals

This update serves to clarify that Invitrogen has divested the Heidelberg, Germany-based unit of its BioReliance business. The BioReliance business itself, which Invitrogen will retain, is based in Rockville, Md. The original story was based on a press release that did not describe the relationship between the Heidelberg and Rockville businesses.

NEW YORK, April 27 (GenomeWeb News) - Invitrogen has sold its BioReliance Manufacturing business to a consortium of investors led by BioReliance's managing director, the company said today.

 

After the management buy-out, which was led by Thomas Pultar, the company will be called BIOMEVA.

 

BioReliance Manufacturing is based in Heidelberg, Germany. It is a "small part" of the overall BioReliance business, based in Rockville, Md., which Invitrogen will retain, according to a company spokesperson.

 

Terms of the divestiture were not disclosed. Invitrogen acquired Rockville-based BioReliance in December 2003 for $500 million.

 

"Bacterial contract manufacturing was not aligned with our strategic direction," Bernd Brust, vice president and general manager for Invitrogen Europe, said in a statement.

 

BioReliance Manufacturing offers fermentation and purification services using recombinant and natural microorganisms. The new company will continue this model, it said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.